

Research Article

Diazepam Potentiates the Antidiabetic, Antistress and Anxiolytic Activities of Metformin in Type-2 Diabetes Mellitus with Cooccurring Stress in Experimental Animals

Debapriya Garabadu and Sairam Krishnamurthy

Neurotherapeutics Lab, Department of Pharmaceutics, Indian Institute of Technology (Banaras Hindu University), Varanasi 221005, India

Correspondence should be addressed to Sairam Krishnamurthy; saibliss@hotmail.com

Received 22 February 2014; Revised 7 May 2014; Accepted 9 May 2014; Published 4 June 2014

Academic Editor: Andrea Mencarelli

Copyright © 2014 D. Garabadu and S. Krishnamurthy. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Psychological stress is considered as one of the limiting factors in the management of type-2 diabetes mellitus (T2DM). Therefore, the basic objective of the present study was to evaluate the antidiabetic effect of metformin, diazepam, and their combination in cooccurring T2DM and stress condition (DMS). T2DM was induced in the male rats by administering streptozotocin (45 mg/kg, *i.p.*) and nicotinamide (110 mg/kg, *i.p.*) with time lag of 15 min. Rats were subjected to two sessions of cold restraint stress paradigm for one hour on the sixth and seventh day after streptozotocin injection. Administration of metformin (25 mg/kg, *p.o.*) and diazepam (1 mg/kg, *p.o.*) in combination from the seventh to thirteenth day after streptozotocin injection showed better improvement in glucose tolerance and insulin sensitivity compared to monotherapy of either drug. In addition, the combination significantly attenuated DMS-induced hyperglycemia, hypertriglyceridaemia, hypercorticosteronemia, anxiety-like behavior, and insulin resistance through modulating insulin signaling pathway in the liver compared to monotherapy. Further, improvement of mitochondrial function, integrity, and oxidative stress in hippocampus, hypothalamus, prefrontal cortex, striatum, amygdala, and nucleus accumbens was observed with the combination. Therefore, metformin in combination with diazepam may be a better therapeutic option in the management of T2DM with cooccurring stress condition.

1. Introduction

Diabetes mellitus is the most common chronic endocrine metabolic disorder. The prevalence of diabetes is rising rapidly worldwide with a projected estimation of about 439 million diabetic people globally by 2030 [1]. The majority of the diabetic patients belong to the type-2 class of diabetes mellitus (T2DM). Considerable research has confirmed biological and behavioral variables as risk factors for the development of T2DM [2]. Psychological distress has long been considered as one of the predisposing factors in the development of T2DM. Stress is an aversive stimulus which disturbs physiological homeostasis and is reported to play an important role in the genesis and pathophysiology of different psychological disorders [3]. Stress can be measured as the actual exposure to events assumed to be stressful, or as an individual's interpretation and perception of stressors

and can be assessed across all contexts of life. However, the role of psychosocial risk factors, including psychological characteristics, social relationships, and stressors, in the development of T2DM has received much less attention.

Only a small number of studies have explored the role of psychosocial stress on the development of diabetes. Clinical studies suggest that there is a strong relationship between psychological stress and diabetes. One study reports that there is one measure of work stress, effort-reward imbalance (a model based on the importance of the reciprocal balance between the effort spent at work and the intrinsic and extrinsic rewards received), and diabetes incidence in men but not in women [4]. In contrast, another measure of work stress, iso-strain (the combination of high demands, low control, and social isolation) as a predictor of diabetes incidence in women but not in men [5]. A meta-analysis of the work stress-diabetes literature failed to show statistically significant relationships

between any individual aspect of work-related stress and risk of diabetes [6]. Recently, a preclinical study reveals that psychological stress after T2DM induction aggravates the progression of diabetes [7]. Thus, psychological stress could be an important factor in the management of T2DM.

Insulin resistance is considered as an important pathophysiological mechanism for the progression to both T2DM and neurodegeneration conditions [8–10]. In most cases, insulin resistance is associated with a complex network of signaling pathways, including reduced insulin-stimulated tyrosine phosphorylation of insulin receptor (IR) and insulin receptor substrate (IRS) as well as Akt serine phosphorylation in the main target tissues of insulin, including the liver, skeletal muscle, and adipose tissue [11, 12]. Several studies have recommended that the phosphorylation levels of IRS-1 on serine residue 307 (IRS-1^{ser307}) and of Akt on serine residue 473 (Akt^{ser473}) in rodents could be used as insulin resistance markers [10, 13, 14]. Thus, information regarding insulin resistance would be crucial in the development of novel drugs in the pharmacotherapy of cooccurring T2DM and stress condition.

Mitochondria are produced in the cell body, transported to specific neuronal locations of increased energy demands such as synapses [15], and play an important role in the neuronal activity pertinent to specific neurotransmitters [16, 17]. Brain mitochondrial function has been reported to decline in both diabetes and stress conditions [18], indicating that mitochondrial dysfunction is common to both disorders. Recently, it has been reported that mitochondrial electron transport chain enzyme activity increased while mitochondrial integrity decreased with the cooccurring T2DM and stress condition in experimental animals [7]. Moreover, both hyperglycemia [19] and stress [20] are reported to elicit an increase in reactive oxygen species production in brain. Increased mitochondrial biogenesis is part of the cellular response to oxidative stress [21]. Therefore, as mitochondria are the common substrate for both T2DM and stress, drugs targeted to mitochondria would be a better therapeutic option in the management of T2DM with cooccurring stress condition.

Metformin (N, N-dimethylimidodicarbonimidic diamide) is one of the most widely used antihyperglycemic agents as the first-line drug therapy for management of T2DM [22, 23]. Metformin inhibits gluconeogenesis through mechanisms linked to perturbation of mitochondrial function [24]. Complex I of mitochondrial respiration chain is considered as one of the possible targets of metformin action [25]. Metformin also inhibits mitochondrial transition pore and mitochondria-linked cell death [26]. Benzodiazepines are commonly prescribed anxiolytics to T2DM patients with history of stress [27, 28]. Diazepam is widely prescribed for the treatment of anxiety, insomnia, or stress disorders. Diazepam augmented the blood glucose level in hyperglycemic rats; however, it did not alter the same in presence of metformin in the animals [29]. Thus, the antihyperglycemic activity of metformin is not impaired in the presence of diazepam. Despite its promising neuroprotective properties, the exact mechanism of diazepam in neuroprotection is not

fully understood. It has also been reported that diazepam acts on translocator proteins apart from other actions such as gamma-amino butyric acid-A receptor stimulation and hypothermia [30]. Translocator proteins located at the contact site between outer and inner mitochondrial membrane and thus regulate the mitochondria-linked apoptosis [31, 32]. Therefore, both metformin and diazepam have mitochondrial effects apart from other reported mechanisms. As stress can influence diabetogenesis, the management of T2DM by the combination therapy could be a better choice over monotherapy.

Therefore, the study evaluates the antihyperglycemic and anti-hypertriglyceridaemic activity of metformin and diazepam in T2DM rats with repeated CRS exposure. The level of corticosterone in the blood and ulcers in the stomach region was estimated as a measure of stress in the T2DM rats with cooccurring stress condition. Further, the potential anxiolytic-like effect of metformin and diazepam was evaluated in the elevated plus maze (EPM) in the above condition. In addition, the antidiabetic, antistress, and anxiolytic-like activity of metformin was evaluated in presence of diazepam in the above condition. At the molecular level, the extent of phosphorylation of IRS-1 and Akt was evaluated to elaborate on the insulin resistance in the above condition. At the subcellular level, mitochondrial function and integrity were investigated in six brain regions such as hippocampus (HIP), hypothalamus (HYP), prefrontal cortex (PFC), striatum (STR), amygdala (AMY), and nucleus accumbens (NAC) to elaborate on the mitochondrial basis of the combination therapy. Oxidative stress markers such as extent of lipid peroxidation (LPO) and antioxidant enzyme activities like superoxide dismutase (SOD) and catalase (CAT) were estimated in the above brain regions to study the mitochondrial-dependent antioxidant mechanism.

2. Materials and Methods

2.1. Animals. Male Charles Foster strain albino rats (200–250 g) were purchased from the Central Animal House, Institute of Medical Sciences, Banaras Hindu University (BHU), and were housed in polypropylene cages under controlled environmental conditions ($25 \pm 1^\circ\text{C}$, 45–55% relative humidity and 12 : 12 h light/dark cycle). All experiments were conducted in compliance with the principles of laboratory animal care (NIH publication number 85–23, revised 1985) guidelines. Experiments on animals were approved by the Institutional Animal Ethics Committee of BHU, Varanasi, India (Protocol number Dean/11-12/CAEC/328). The animals had free access to commercial rat feed (Doodh dhara Pashu Ahar, India) and water *ad libitum* unless stated otherwise during the experiment. Animals were acclimatized for at least one week before using them for experiments and exposed only once to every experiment.

2.2. Chemicals. Streptozotocin, thiobarbituric acid (TBA), tetra methyl rhodamine methyl ester (TMRM), and dexamethasone were procured from Sigma (St. Louis, MO, USA). Antibodies such as phospho-IRS-1^{ser307}, total IRS,

phosphor-Akt^{ser473}, total Akt, and beta-actin were purchased from Abcam Plc., Cambridge, USA. All other chemicals and reagents were available commercially from local suppliers and were of analytical grade.

2.3. Induction of Cooccurring T2DM and Repeated CRS (DMS). The T2DM was induced in overnight fasted rats by a single injection of streptozotocin (45 mg/kg, i.p.), 15 min after nicotinamide (110 mg/kg, i.p.) administration. Streptozotocin was dissolved in 0.1M citrate buffer (pH 4.5) and nicotinamide was dissolved in physiological saline [33]. Further, two stress sessions 24 hr apart were performed during 08:00 hr to 12:00 hr on the 6th and 7th day of streptozotocin injection and were consisting of a 1hr restraint period (rat restrainers were transparent plastic tubes 15 cm long × 6.5 cm width) in a 4°C room [7, 34].

2.4. The Experimental Design. The experimental design consists of three sets of experiments. The animals were acclimatized for seven days and were randomly divided into five groups, namely, control, diabetes with repeated CRS (DMS), DMS + MET, DMS + DZ, and DMS + MET + DZ in each of the experiment. The experimental protocol was followed for 13 days for all experiments. The day animals received the streptozotocin injection was considered as day-1(D-1). The rats were exposed to repeated CRS procedures to all the group animals except control group rats on D-6 and D-7. On D-7, after 1hr to CRS paradigm, metformin (25 mg/kg, *p.o.*; [35]) was administered to DMS + MET and DMS + MET + DZ group animals while diazepam (1 mg/kg, *p.o.*; [36, 37]) was administered to DMS + DZ and DMS + MET + DZ group rats after 30 min to metformin treatment. This treatment schedule was continued for seven consecutive days, that is, D-13 of the experimental design. The experiments 1 and 2 were performed for the oral glucose tolerance test (OGTT) and insulin tolerance test (ITT), respectively. In experiment 3, all the animals were killed after 1hr to the last dose on D-13 of the experimental schedule by decapitation. The blood and liver were stored immediately at -80°C till further study. The brains were removed and microdissected [38] into hippocampus (HIP), hypothalamus (HYP), prefrontal cortex (PFC), striatum (STR), amygdala (AMY), and nucleus accumbens (NAC) and stored immediately at -80°C till further study.

2.5. Oral Glucose Tolerance Test (OGTT). Oral glucose tolerance test (OGTT) is considered as a classical and model-based estimate of beta-cell function [39]. The OGTT was performed on overnight fasted rats on the 13th day of the experimental schedule. Metformin, diazepam, their combination, and vehicle were administered 60 min prior to glucose administration (2 g/kg, i.g.). The blood samples were collected through retroorbital puncture just before glucose load (0 min) and at 30, 60, and 120 min after glucose administration. Plasma glucose concentrations were determined with glucose GOD PAP kit (Priman Instrument Pvt. Ltd., India) based on glucose oxidase method [40].

2.6. Insulin Tolerance Test (ITT). Insulin tolerance test (ITT) is a simple and reliable method of estimating insulin sensitivity [41, 42]. The ITT was performed on overnight fasted rats on the 13th day of the experimental schedule. Metformin, diazepam, their combination, and vehicle were administered 60 min prior to insulin administration (0.4 IU/kg, s.c.). The blood samples were collected through retroorbital puncture just before glucose load (0 min) and at 30, 60, and 90 min after glucose administration. Plasma glucose concentrations were determined with glucose GOD PAP kit (Priman Instrument Pvt. Ltd., India) based on glucose oxidase method [40].

2.7. Estimation of Plasma Glucose and Triglyceride Level. On the D-1, 3, 7, and 13 of the experimental protocol, 1mL of blood was collected through retroorbital puncture and centrifuged at 3000 ×g for 5 min at 4°C [43] to obtain plasma for measuring the glucose, triglyceride, and corticosterone levels. The plasma glucose and triglyceride was determined spectrophotometrically (Beckman Coulter DU 7400 UV-VIS Spectrophotometer, Fullerton, CA) in triplicate using the glucose GOD PAP kit (Priman Instrument Pvt. Ltd., India) and triglyceride GPO-PAP kit (Span Diagnostics Ltd., India), respectively.

2.8. Estimation of Plasma Corticosterone Level. The plasma corticosterone was quantified in a High Performance Liquid Chromatography (HPLC) with Ultraviolet (UV) detector system (Waters, USA), according to Woodward and Emery [44] with minor modifications using dexamethasone as an internal standard [45]. Briefly, 500 μL of plasma containing known quantity of dexamethasone was extracted with 5 mL of dichloromethane. The dichloromethane extract was evaporated to dryness and dissolved in 100 μL of mobile phase. Twenty microliters of extract was injected into HPLC system for quantification. Mobile phase consisted of methanol : water (70 : 30) at a flow rate of 1.2 mL/min and CORT was detected at 250 nm using UV detector (Model 2849, Waters, USA). The chromatogram was recorded and analyzed with Empower software (Version 2.0).

2.9. Estimation of Ulcer Index. The stomach was cut through greater curvature and a blind observer calculated the ulcer index by following standard protocol [46].

2.10. Anxiety-Like Behavior in EPM Test. The plus maze consisted of two opposite open arms, 50×10 cm, crossed with two opposite open arms of the same dimensions with walls of 40 cm high. The arms were connected with a central square (10×10 cm) to give the apparatus a plus-sign appearance. The maze was kept elevated 50 cm above the floor in a dimly lit room. The rats were placed individually on the central square of the plus maze facing an enclosed arm. The percentage time spent and the numbers of entries made by the rat, during the next 5 min, on the open arms were recorded as an index of anxiety. Further, the total arm entries were recorded as an index of locomotor activity. An arm entry was defined when all four limbs of the rat were on the arm [47].

2.11. Western Blot Analysis. For Western blot analysis, the liver tissues were lysed in buffer containing complete protease inhibitor cocktail. Protein concentrations were determined according to Bradford (1976; [48]). A standard plot was generated using bovine serum albumin. An aliquot of each sample was electrophoresed in 10% SDS-PAGE gels for phospho-IRS-1^{ser307}, total IRS, phospho-Akt^{ser473}, and total Akt proteins, transferred to polyvinylidene fluoride membranes and probed with specific antibodies. The membrane was incubated overnight with polyclonal rabbit anti-phospho-IRS-1^{ser307} (1:10,000, Abcam Plc., Cambridge, USA), monoclonal anti-total IRS (1:1000, Abcam Plc., Cambridge, USA), monoclonal anti-phospho-Akt^{ser473} (1:10,000, Abcam Plc., Cambridge, USA), and polyclonal anti-total Akt (1:1000, Abcam Plc., Cambridge, USA) primary antibodies. After detection with the desired antibodies against the proteins of interest, the membrane was stripped with stripping buffer (25 mM Glycine pH 2.0, 2% SDS) for 30 min at room temperature and reprobed overnight with rabbit anti- β -actin polyclonal primary antibody (Abcam Plc., Cambridge, USA) at a dilution of 1:500 to confirm equal loading of protein. Further, membrane was probed with corresponding secondary antibodies. Immunoreactive band of proteins were detected by chemiluminescence using enhanced chemiluminescence (ECL) reagents (Amersham Bioscience, USA). Quantification of the results was performed by densitometric scan of films. The immunoreactive area was determined by densitometric analysis using Biovis gel documentation software.

2.12. Assessment of Mitochondrial Function, Integrity, and Oxidative Stress

2.12.1. Mitochondria Isolation Procedure. Mitochondria were isolated by following standard procedure of Pedersen et al. [49]. Briefly, the brain regions were homogenized in (1:10, w/v) ice cold isolation buffer (250 mM sucrose, 1 mM EGTA, and 10 mM HEPES-KOH, pH 7.2) followed by centrifugation at 600 \times g/5 min. The resultant supernatant was centrifuged at 10,000 \times g/15 min. The resultant pellets were suspended in 1 mL medium (250 mM sucrose, 0.3 mM EGTA, and 10 mM HEPES-KOH, pH 7.2) and again centrifuged at 14,000 \times g/10 min. All centrifugation procedures were performed at 4°C. The final mitochondrial pellet was resuspended in medium (250 mM sucrose and 10 mM HEPES-KOH, pH 7.2) and used within 3 h. The mitochondrial protein content was estimated using the method of Lowry et al. [50].

2.12.2. Estimation of Mitochondrial Succinate Dehydrogenase (SDH) Activity. The mitochondrial SDH was determined by following the method of Old and Johnson [51] based on the progressive reduction of NBT to diformazan (dfz) measured at 570 nm. The mean SDH activity of each region was expressed as micromole formazan produced per min per milligram of protein.

2.12.3. Estimation of Mitochondrial Membrane Potential (MMP). The Rhodamine dye taken up by mitochondria was measured with spectrofluorometer (Hitachi, F-2500, Japan;

[52]). Briefly, the mitochondrial suspension was mixed with TMRM solution and incubated for 5 min at 25°C followed by frequent washings (four times) to remove any unbound TMRM. The fluorescence emission was read at an excitation λ of 535 \pm 10 nm and emission λ of 580 \pm 10 nm using slit no. 10. The peak fluorescence intensity recorded was around 570 \pm 5 nm. The intensity of fluorescence was recorded which was considered to be proportional to MMP.

2.12.4. Estimation of Mitochondrial Lipid Peroxidation (LPO). Mitochondrial MDA content was measured as a marker for LPO described by Uchiyama and Mihara [53] and modified by Sunderman et al. [54]. Briefly, the chromophore formed in the reaction was measured at 532 nm. The MDA concentrations are expressed as micromoles of MDA/mg of protein.

2.12.5. Estimation of Mitochondrial Superoxide Dismutase (SOD) Activity. The activity of SOD was assayed by the method of Kakkar et al. [55] based on the formation of NADH-phenazine methosulphate-nitro blue tetrazolium formazan measured at 560 nm against butanol as blank. A single unit of the enzyme was expressed as 50% inhibition of NBT reduction/min/mg of protein under the assay conditions.

2.12.6. Estimation of Mitochondrial Catalase (CAT) Activity. Decomposition of hydrogen peroxide in presence of CAT was followed at 240 nm [56]. The results were expressed as units (U) of CAT activity/min/mg of protein.

2.13. Data Analysis. The results were expressed as mean \pm S.E.M. The statistical significance for time-course effects on plasma glucose, TG, and CORT levels and parameters in the EPM test paradigm was analyzed by two-way analysis of variance (ANOVA) followed by post hoc Bonferroni test. All other datasets were analyzed by one-way ANOVA followed by post hoc Student Newman-Keuls test. $P < 0.05$ was considered to be statistically significant throughout the experimental data analysis.

3. Results

3.1. Metformin and Diazepam Combination Enhanced Glucose Tolerance during OGTT in DMS Rats More Than Metformin or Diazepam Monotherapy. Table 1 illustrates the effect of metformin or diazepam or their combination on plasma glucose levels during OGTT in DMS exposed rats. Repeated measures of two-way ANOVA revealed that there were significant differences in plasma glucose levels among group ($F(4, 100) = 1432; P < 0.05$), time ($F(3, 100) = 418.1; P < 0.05$), and an interaction ($F(12, 100) = 52.5; P < 0.05$) between group and time. Post hoc analysis showed that metformin but not diazepam monotherapy decreased the glucose level at 30 min after glucose loading compared to DMS rats. Moreover, the combination of metformin and diazepam showed remarkable improvement in glucose response at 30 min after glucose loading compared to metformin monotherapy. This effect persisted up to 120 min after glucose loading during OGTT.

TABLE 1: Effect of metformin, diazepam, or their combination on plasma glucose level during OGTT in cooccurring T2DM and RS exposed rats.

Groups	Plasma glucose level (mg/dL)			
	0 min	30 min	60 min	120 min
Control	74.3 ± 1.3	143.6 ± 1.8	157.3 ± 3.9	111.5 ± 3.8
DMS	512.4 ± 12.9 ^a	969.2 ± 34.3 ^a	1202.8 ± 26.0 ^a	1192.7 ± 21.8 ^a
DMS + MET	420.3 ± 6.6 ^{a,b}	609.6 ± 25.5 ^{a,b}	690.0 ± 23.5 ^{a,b}	555.6 ± 24.2 ^{a,b}
DMS + DZ	499.0 ± 9.7 ^{a,c}	941.9 ± 23.0 ^{a,c}	1156.6 ± 16.2 ^{a,c}	1188.5 ± 29.0 ^{a,c}
DMS + MET + DZ	206.9 ± 4.3 ^{a,b,c,d}	445.5 ± 24.0 ^{a,b,c,d}	448.7 ± 26.0 ^{a,b,c,d}	426.3 ± 9.0 ^{a,b,c,d}

All values are mean ± SEM ($n = 6$). ^a $P < 0.05$ compared to control, ^b $P < 0.05$ compared to DMS, ^c $P < 0.05$ compared to DMS + MET, and ^d $P < 0.05$ compared to DMS + DZ (repeated measures of two-way ANOVA followed by Bonferroni post hoc test).

TABLE 2: Effect of metformin, diazepam, or their combination on plasma glucose level during ITT in cooccurring T2DM and RS exposed rats.

Groups	Plasma glucose level (mg/dL)			
	0 min	30 min	60 min	90 min
Control	73.2 ± 2.6	58.1 ± 3.4	56.4 ± 3.3	54.3 ± 4.2
DMS	510.5 ± 12.3 ^a	448.3 ± 18.9 ^a	439.7 ± 19.7 ^a	437.0 ± 21.5 ^a
DMS + MET	418.4 ± 5.6 ^{a,b}	395.9 ± 4.5 ^{a,b}	393.8 ± 3.7 ^{a,b}	390.0 ± 4.1 ^{a,b}
DMS + DZ	493.3 ± 9.2 ^{a,c}	437.6 ± 9.5 ^{a,c}	431.2 ± 10.6 ^{a,c}	427.0 ± 9.4 ^{a,c}
DMS + MET + DZ	203.1 ± 5.0 ^{a,b,c,d}	146.4 ± 3.9 ^{a,b,c,d}	142.1 ± 3.8 ^{a,b,c,d}	140.0 ± 3.3 ^{a,b,c,d}

All values are mean ± SEM ($n = 6$). ^a $P < 0.05$ compared to control, ^b $P < 0.05$ compared to DMS, ^c $P < 0.05$ compared to DMS + MET, and ^d $P < 0.05$ compared to DMS + DZ (repeated measures of two-way ANOVA followed by Bonferroni post hoc test).

3.2. Metformin and Diazepam Combination Increased Insulin Sensitivity during ITT in DMS Rats More Than Metformin or Diazepam Monotherapy. Table 2 illustrates the effect of metformin or diazepam or their combination on plasma glucose levels during ITT in DMS exposed rats. Repeated measures of two-way ANOVA revealed that there were significant differences in plasma glucose levels among group ($F(4, 100) = 1392$; $P < 0.05$), time ($F(3, 100) = 28.5$; $P < 0.05$), and an interaction ($F(12, 100) = 1.5$; $P < 0.05$) between group and time. Post hoc analysis showed that metformin but not diazepam monotherapy decreased significantly the plasma glucose level at 30 min after insulin injection compared to DMS rats. Moreover, the combination of metformin and diazepam showed remarkable improvement in insulin sensitivity at 30 min after insulin injection compared to metformin monotherapy. This effect persisted up to 90 min after insulin injection during ITT.

3.3. Metformin and Diazepam Combination Reduced DMS-Induced Increase in the Plasma Glucose, Triglyceride, and Corticosterone Levels in Rats More Than Metformin or Diazepam Monotherapy. Table 3 illustrates the effect of metformin or diazepam or their combination on DMS-induced alterations in plasma glucose, triglyceride, and corticosterone levels. Repeated measures of two-way ANOVA revealed that there were significant differences in plasma glucose, triglyceride, and corticosterone levels among group ($F(4, 100) = 6220$; $P < 0.05$), ($F(4, 100) = 746.2$; $P < 0.05$) and ($F(4, 100) = 350.7$; $P < 0.05$), resp.), time ($F(3, 100) = 15570$; $P < 0.05$), ($F(3, 100) = 2027$; $P < 0.05$) and ($F(3, 100) = 1525$; $P < 0.05$), resp.) and an interaction ($F(12, 100) = 1568$; $P < 0.05$), ($F(12, 100) = 231.3$; $P < 0.05$),

and ($F(12, 100) = 126.9$; $P < 0.05$), resp.) between group and time. Post hoc analysis showed that there were no significant differences among groups in plasma glucose or triglyceride or corticosterone levels on D-1. Streptozotocin injection caused significant increase in the plasma glucose, triglyceride, and corticosterone levels on D-3 of the experimental schedule compared to vehicle treated rats. Further, exposure to repeated CRS augmented the levels of plasma glucose, triglyceride, and corticosterone on D-7 compared to control animals. Metformin treatment significantly decreased the DMS-induced increase in all the biochemical parameters in the plasma on D-13 of the experimental schedule. However, diazepam significantly reduced the DMS-induced increase in the level of corticosterone only in the plasma of the rats. Furthermore, metformin and diazepam combination significantly reduced the DMS-induced increase in all the biochemical parameters in the plasma on D-13 compared to metformin and diazepam monotherapy.

3.4. Diazepam in Combination with Metformin Reduced Gastric Ulcer in DMS Exposed Rats More Than Either Metformin or Diazepam Monotherapy. The effect of metformin or diazepam or their combination on DMS-induced gastric ulcer in rats is depicted in Figure 1. Statistical analysis by one-way ANOVA revealed that there were significant differences in gastric ulcer index ($F(4, 25) = 49.29$; $P < 0.05$) among groups on D-13. Post hoc test showed that DMS induced significant increase in the gastric ulcers in rats compared to vehicle treated animals. Administration of either metformin or diazepam significantly reduced the DMS-induced increase in the gastric ulcers in rats. Moreover, diazepam treated rats showed significant decrease in the DMS-induced

TABLE 3: Effect of metformin, diazepam, or their combination on plasma glucose, triglyceride, and corticosterone levels in cooccurring T2DM and RS exposed rats.

Groups	D-1	D-3	D-7	D-13
Plasma glucose (mg/dL)				
Control	76.3 ± 1.0	75.8 ± 0.8	75.5 ± 0.6	75.1 ± 0.8
DMS	76.0 ± 2.8	256.3 ± 3.0 ^a	568.8 ± 5.8 ^a	577.6 ± 2.5 ^a
DMS + MET	74.5 ± 2.7	261.1 ± 2.5 ^a	572.9 ± 5.1 ^a	425.8 ± 4.7 ^{a,b}
DMS + DZ	75.3 ± 1.7	254.3 ± 2.7 ^a	566.2 ± 4.8 ^a	574.2 ± 1.8 ^{a,c}
DMS + MET + DZ	74.9 ± 2.6	264.6 ± 1.3 ^a	574.1 ± 0.7 ^a	212.5 ± 5.2 ^{a,b,c,d}
Plasma triglyceride (mg/dL)				
Control	85.9 ± 1.5	87.4 ± 1.6	87.3 ± 1.6	87.1 ± 1.5
DMS	90.5 ± 1.2	195.2 ± 4.1 ^a	471.0 ± 9.8 ^a	483.3 ± 10.1 ^a
DMS + MET	88.8 ± 1.5	194.1 ± 7.0 ^a	474.2 ± 11.1 ^a	365.6 ± 9.0 ^{a,b}
DMS + DZ	91.3 ± 1.2	196.2 ± 4.8 ^a	470.1 ± 9.8 ^a	484.1 ± 9.6 ^{a,c}
DMS + MET + DZ	91.7 ± 1.2	200.0 ± 5.7 ^a	484.9 ± 12.6 ^a	146.0 ± 7.1 ^{a,b,c,d}
Plasma corticosterone (µg/dL)				
Control	15.8 ± 0.4	16.3 ± 0.4	15.9 ± 0.4	16.1 ± 0.5
DMS	15.9 ± 0.3	34.4 ± 1.5 ^a	187.7 ± 5.3 ^a	191.5 ± 8.8 ^a
DMS + MET	15.4 ± 0.6	32.0 ± 1.1 ^a	188.4 ± 5.7 ^a	120.5 ± 3.9 ^{a,b}
DMS + DZ	15.2 ± 0.7	31.7 ± 1.0 ^a	186.7 ± 6.5 ^a	107.1 ± 2.6 ^{a,b,c}
DMS + MET + DZ	15.4 ± 0.7	31.3 ± 1.0 ^a	191.1 ± 6.0 ^a	77.6 ± 5.5 ^{a,b,c,d}

All values are mean ± SEM ($n = 6$). ^a $P < 0.05$ compared to control, ^b $P < 0.05$ compared to DMS, ^c $P < 0.05$ compared to DMS + MET, and ^d $P < 0.05$ compared to DMS + DZ (repeated measures of two-way ANOVA followed by Bonferroni post hoc test).




FIGURE 1: The effect of metformin (MET), diazepam (DZ), and their combination on gastric ulcer in T2DM and repeated CRS paradigm (DMS) exposed rats. All values are mean ± SEM ($n = 6$). ^a $P < 0.05$ compared to control, ^b $P < 0.05$ compared to DMS, ^c $P < 0.05$ compared to DMS + MET, and ^d $P < 0.05$ compared to DMS + DZ (one-way ANOVA followed by Student Newmann-Keuls test).

gastric ulcers compared to metformin administered animals. Furthermore, administration of both diazepam and metformin significantly decreased the DMS-induced increase in the gastric ulcers compared to metformin and diazepam monotherapy.

3.5. Metformin and Diazepam Combination Exhibited Better Anxiolytic Activity in DMS Exposed Rats More Than Their Monotherapy. Figure 2 illustrates the effect of metformin or diazepam or their combination on percentage of open arm entries to total arm entries Figure 2(a) and percentage of open arm time spent to total arm time spent Figure 2(b), and total arm entries Figure 2(c) in EPM test paradigm of DMS exposed rats. Statistical analysis by repeated measures of two-way ANOVA revealed that there were significant differences in percentage open arm entries and time spent among groups (($F(4, 50) = 40.97; P < 0.05$) and ($F(4, 50) = 34.65; P < 0.05$), resp.), time (($F(1, 50) = 52.99; P < 0.05$) and ($F(1, 50) = 22.80; P < 0.05$), resp.) and an interaction between group and time (($F(4, 50) = 7.66; P < 0.05$) and ($F(4, 50) = 4.79; P < 0.05$), resp.). However, there were no significant differences in total arm entries in EPM paradigm among group ($F(4, 50) = 0.72; P > 0.05$), time ($F(1, 50) = 9.92; P > 0.05$), and there was no significant interaction between group and time ($F(4, 50) = 0.90; P > 0.05$). Post hoc analysis showed that DMS paradigm caused significant increase in the percentage open arm entries and time spent on D-7 compared to control rats and was sustained up to D-13. Metformin and diazepam significantly ameliorated the DMS-induced increase in the percentage open arm entries and time spent in the EPM test. Moreover, treatment of both diazepam and metformin significantly reduced the DMS-induced increase in the percentage open arm entries and time spent compared to metformin and diazepam administration.

3.6. Metformin and Diazepam Combination Enhanced the Serine Phosphorylation of $IRS-1^{ser307}$ and Akt^{ser473} in the Liver




FIGURE 2: The effect of MET, DZ, and their combination on DMS-induced alterations in percentage of open arm entries to total arm entries (a), percentage of open arm time spent to total arm time spent (b), and total arm entries (c) in EPM. All values are mean \pm SEM ($n = 6$). ^a $P < 0.05$ compared to control, ^b $P < 0.05$ compared to DMS, ^c $P < 0.05$ compared to DMS + MET, and ^d $P < 0.05$ compared to DMS + DZ (repeated measure two-way ANOVA followed by Bonferroni test).

of DMS Exposed Rats More Than Their Monotherapy. Figures 3 and 4 depict the effect of metformin and diazepam or their combination on the DMS-induced alterations in the level of phosphorylation of IRS-1^{ser307} and Akt^{ser473} in the liver tissues, respectively. Statistical analysis by one-way ANOVA revealed that there were significant differences in the level of expression of p-IRS-1^{ser307} ($F(4, 10) = 62.14; P < 0.05$) and p-Akt^{ser473} ($F(4, 10) = 75.40; P < 0.05$), and ratio of p-IRS-1^{ser307}/total IRS ($F(4, 10) = 34.18; P < 0.05$) and p-Akt^{ser473}/total Akt ($F(4, 10) = 56.26; P < 0.05$) in the liver tissues among groups. However, there were no significant differences in the level of expression of total IRS-1 ($F(4, 10) = 0.47; P > 0.05$) and Akt ($F(4, 10) = 0.21; P > 0.05$) in the liver tissues among groups. Post hoc analysis showed that DMS exposure significantly reduced the extent of phosphorylation of IRS-1^{ser307} and Akt^{ser473} in the rat liver tissues. Metformin but not diazepam significantly mitigated the DMS-induced decrease in the extent of phosphorylation of IRS-1^{ser307} and

Akt^{ser473} in the liver. Moreover, metformin with diazepam combination further ameliorated the DMS-induced decrease in the extent of phosphorylation of IRS-1^{ser307} and Akt^{ser473} in the liver compared to metformin monotherapy.

3.7. Effect of Metformin or Diazepam or Their Combination on DMS-Induced Alterations in Mitochondrial SDH and MMP in Discrete Brain Regions. Figure 5 depicts the effect of metformin, diazepam, or their combination on DMS-induced changes in mitochondrial SDH and MMP in different brain regions. Statistical analysis by one-way ANOVA revealed that there were significant differences in percentage in mitochondrial SDH and MMP in HIP ($(F(4, 25) = 72.12; P < 0.05)$ and $(F(4, 25) = 75.19; P < 0.05)$, resp.), HYP ($(F(4, 25) = 50.29; P < 0.05)$ and $(F(4, 25) = 70.10; P < 0.05)$, resp.), PFC ($(F(4, 25) = 32.54; P < 0.05)$ and $(F(4, 25) = 43.08; P < 0.05)$, resp.), STR ($(F(4, 25) = 6.91; P < 0.05)$ and $(F(4, 25) = 56.40; P < 0.05)$, resp.), AMY ($(F(4, 25) = 54.94;$




FIGURE 3: The effect of MET, DZ, and their combination on DMS-induced changes in the level of expression of phospho-IRS^{ser307} (p-IRS^{ser307}) and total IRS in the liver tissues. The blots are representative of p-IRS^{ser307} and total IRS (a) in the liver tissues. The results in the histogram are expressed as a ratio of relative intensity of levels of protein expression of either p-IRS^{ser307} or total IRS to β-actin and a ratio of relative intensity of level of expression of p-IRS^{ser307} to total IRS. All values are mean ± SEM of three separate sets of independent experiments. ^a $P < 0.05$ compared to control, ^b $P < 0.05$ compared to DMS, ^c $P < 0.05$ compared to DMS + MET, and ^d $P < 0.05$ compared to DMS + DZ (one-way ANOVA followed by Student Newmann-Keuls test).

$P < 0.05$) and (F (4, 25) = 50.94; $P < 0.05$), resp.) and NAC ((F (4, 25) = 30.04; $P < 0.05$) and (F (4, 25) = 35.41; $P < 0.05$), resp.) among groups. Post hoc test showed that metformin and diazepam monotherapy significantly reversed the DMS-induced increase and decrease in the mitochondrial SDH and MMP, respectively, in all the brain regions. Furthermore, administration of combination of metformin and diazepam caused significant reduction in the DMS-induced increase and decrease in the mitochondrial SDH and MMP, respectively, in all the brain regions compared to their monotherapy.

3.8. Effect of Metformin or Diazepam or Their Combination on DMS-Induced Alterations in Mitochondrial LPO and Activities

of SOD and CAT in Discrete Brain Regions. The effect of metformin or diazepam or their combination on DMS-induced changes in mitochondrial LPO and activities of SOD and CAT in different brain regions is illustrated in Figure 6. One-way ANOVA revealed that there were significant differences in percentage in mitochondrial LPO and activities of SOD and CAT in HIP ((F (4, 25) = 38.73; $P < 0.05$), (F (4, 25) = 22.26; $P < 0.05$) and (F (4, 25) = 35.26; $P < 0.05$), resp.), HYP ((F (4, 25) = 57.62; $P < 0.05$), (F (4, 25) = 25.43; $P < 0.05$) and (F (4, 25) = 43.28; $P < 0.05$), resp.), PFC ((F (4, 25) = 54.30; $P < 0.05$), (F (4, 25) = 41.21; $P < 0.05$) and (F (4, 25) = 32.11; $P < 0.05$), resp.), STR ((F (4, 25) = 31.44; $P < 0.05$), (F (4, 25) = 21.71; $P < 0.05$) and (F (4, 25) = 52.08; $P < 0.05$), resp.), AMY ((F (4, 25) = 24.00; $P < 0.05$), (F (4, 25) = 63.25;




FIGURE 4: The effect of MET, DZ, and their combination on DMS-induced changes in the level of expression of phospho-Akt^{ser473} (p-Akt^{ser473}) and total Akt in the liver tissues. The blots are representative of p-Akt^{ser473} and total Akt (a) in the liver tissues. The results in the histogram are expressed as a ratio of relative intensity of levels of protein expression of either p-Akt^{ser473} or total Akt to β-actin and a ratio of relative intensity of level of expression of p-Akt^{ser473} to total Akt. All values are mean ± SEM of three separate sets of independent experiments. ^a*P* < 0.05 compared to control, ^b*P* < 0.05 compared to DMS, ^c*P* < 0.05 compared to DMS + MET, and ^d*P* < 0.05 compared to DMS + DZ (one-way ANOVA followed by Student Newmann-Keuls test).

P < 0.05) and (*F* (4, 25) = 42.03; *P* < 0.05), resp.) and NAC ((*F* (4, 25) = 29.49; *P* < 0.05), (*F* (4, 25) = 45.42; *P* < 0.05) and (*F* (4, 25) = 46.26; *P* < 0.05), resp.) among groups. Post hoc test revealed that metformin and diazepam monotherapy significantly decreased the DMS-induced increase in the mitochondrial LPO in all the brain regions. Administration of both metformin and diazepam further decreased the DMS-induced increase in the mitochondrial LPO in all the brain regions compared to metformin and diazepam monotherapy. Moreover, metformin and diazepam monotherapy caused significant increase in the DMS-induced decrease in the activities of mitochondrial SOD and CAT in all the brain regions. Administration of metformin and diazepam combination further increased the DMS-induced decrease in

the mitochondrial SOD and CAT in all the brain regions compared to their monotherapy.

4. Discussion

The primary objective of the present study was to evaluate the antidiabetic efficacy of metformin and diazepam in co-occurring T2DM and repeated CRS exposed rats. Additionally, the study also examined the effect of coadministration of metformin and diazepam for antidiabetic, antistress, and anxiolytic-like activities in the above model. Metformin exhibited antidiabetic, antistress, and anxiolytic-like activities in the cooccurring condition of T2DM and stress. However,




FIGURE 5: The effect of MET, DZ, and their combination on mitochondrial succinate dehydrogenase (SDH) activity and membrane potential in discrete brain regions in DMS exposed rats. All values are mean \pm SEM ($n = 6$). ^a $P < 0.05$ compared to control, ^b $P < 0.05$ compared to DMS, ^c $P < 0.05$ compared to DMS + MET, and ^d $P < 0.05$ compared to DMS + DZ (one-way ANOVA followed by Student Newman-Keuls test).

diazepam showed antistress and anxiolytic-like activities but not antidiabetic activity in the above condition. Metformin and diazepam combination enhanced antidiabetic, antistress, and anxiolytic-like activities compared to metformin treatment in cooccurring T2DM and repeated CRS exposed rats. We for the first time report that the combination therapy improved the glucose tolerance and insulin sensitivity in the cooccurring T2DM and stress condition. Further, the combination improved the insulin resistance in the liver of cooccurring T2DM and repeated CRS exposed rats. The combination therapy showed marked improvement in mitochondrial function, integrity, and oxidative stress in all the brain regions in the above condition more than their monotherapy. Thus, metformin in combination with diazepam would be a better therapeutic option in the management of cooccurring T2DM and stress condition.

To assess the effect of metformin, diazepam, and their combination on cooccurring T2DM and stress condition-induced disturbance in the glucose homeostasis, the OGTT and ITT were performed. OGTT is an important index for the evaluation of beta cell function while ITT indicates the insulin sensitivity [57]. The impairment in glucose tolerance and insulin sensitivity during T2DM is reported to be improved by metformin treatment [40, 58]. In the present study, the co-occurring condition impaired glucose tolerance and insulin sensitivity. Metformin, but not

diazepam monotherapy, improved glucose tolerance in the above cooccurring condition. Interestingly, the improvement of glucose tolerance in the cooccurring condition was better with combination therapy than metformin monotherapy. Moreover, the combination improved insulin sensitivity in the cooccurring condition of T2DM and stress compared to metformin monotherapy. These results suggest the fact that the combination may have potential therapeutic effect on the insulin signaling pathway in the above condition.

Experimental as well as clinical studies report hyperglycemia and aberrant lipid profile in T2DM with stress condition [7, 59–61]. Similar to earlier findings, the levels of glucose and triglyceride were elevated with the cooccurring T2DM and stress exposure. Metformin exhibited antidiabetic activity in terms of reducing glucose as well as triglyceride in the rats exposed to both T2DM and stress paradigm. Metformin decreases T2DM-induced increase in the level of glucose and triglyceride in the plasma of both animals and patients [62, 63]. However, this is the first report of effect of metformin on the rats exposed to both T2DM and stress paradigm. Further, metformin in presence of diazepam exhibited pronounced antihyperglycemic and anti-hypertriglyceridaemic effect than metformin monotherapy in cooccurring T2DM and stress exposed rats. In an earlier report, it has been documented that diazepam treatment augmented the hyperglycemic condition in hyperglycemic rats and this effect was ameliorated with metformin administration [29]. However, in the present study diazepam did not alter the hyperglycemic condition in the cooccurring condition of T2DM and stress. This discrepancy could be due to both the mode of induction of diabetes and the presence of stress. These effects indicate that this combination shows prominent antidiabetic effect in terms of reducing blood glucose and triglyceride levels in cooccurring T2DM and stress condition.

It is demonstrated that hypercorticonemia is observed in both T2DM and stress conditions and also in their cooccurring situation [7, 64–66], a result of overactivation of hypothalamic-pituitary-adrenal cortex-(HPA-) axis function [67]. Similar to earlier observations, there was significant increase in the level of corticosterone in the plasma in cooccurring T2DM and stress exposed animals in the current study. In addition, this cooccurring condition exhibited significant ulcers in the stomach of the animals providing further evidence as a peripheral marker of HPA-axis dysfunction. Diazepam potentiated the antistress activity of metformin in the T2DM rats exposed to repeated stress paradigm in terms of reducing in the plasma corticosterone and gastric ulceration more than metformin and diazepam monotherapy. Similar to our findings, metformin regulated plasma corticosterone in T2DM subjects [68, 69]. However, the mechanism of reduction of corticosterone by metformin is still not clear. It has also been postulated that metformin exhibits the antidiabetic effect by downregulating the glucocorticoid receptors in the brain tissues of rats with hypercorticonemia [68]. Diazepam modulates HPA-axis function during stress conditions and thus reduces the level of plasma corticosterone in both animals and patients [27, 30]. It has been suggested that activation




FIGURE 6: The effect of MET, DZ, and their combination on mitochondrial lipid peroxidation (LPO) and superoxide dismutase (SOD) and catalase (CAT) activities in discrete brain regions in DMS exposed rats. All values are mean \pm SEM ($n = 6$). ^a $P < 0.05$ compared to control, ^b $P < 0.05$ compared to DMS, ^c $P < 0.05$ compared to DMS + MET, and ^d $P < 0.05$ compared to DMS + DZ (one-way ANOVA followed by Student Newman-Keuls test).

of corticosteroid receptors plays a significant role in the pathogenesis of anxiety-like behaviors in diabetic rats [70]. Further, corticosteroid receptor antagonists synergize the anxiolytic-like activity of diazepam in the diabetic rats [70]. Thus, it can be assumed that the metformin and diazepam in combination exhibited antistress effect in cooccurring diabetic-stress condition probably acting through a common corticosteroid-dependent mechanism. This contention, however, has to be further investigated.

T2DM patients more vulnerable to stress-related disorders such as anxiety have been associated with poor glycemic control [71, 72]. Diabetic patients with anxiety disorders have shown much pronounced hyperglycemia [73]. Thus, it is assumed that successful treatment of anxiety may improve glycemic control in T2DM subjects. In the present study, cooccurring T2DM and CRS condition exhibited anxiety-like symptoms on D-7 of the streptozotocin injection in the EPM test paradigm and this effect was sustained up to D-13 of the experimental schedule. The anxiety-like behavior is well documented in diabetes [74]. However, this is the first study where T2DM rats exposed to repeated stress paradigm showed anxiety-like behaviour. Metformin and diazepam treatment for seven consecutive days attenuated the anxiety-like symptoms in experimental rats exposed to both T2DM and repeated CRS paradigm. Metformin in presence of diazepam caused remarkable reduction in the anxiety-like symptoms in experimental animals exposed to both T2DM and repeated CRS paradigm. The results indicate better anxiolytic-like effect of the combination over either

metformin or diazepam monotherapy in these conditions in addition to antidiabetic activity.

The combined results of OGTT and ITT demonstrate that there is impairment in the insulin signaling pathway in the cooccurring T2DM and stress exposed animals. Both metformin and its combination with diazepam therapy showed improvement in the insulin signaling pathway in the above condition. To elaborate on the insulin resistance, we evaluated the extent of phosphorylation of IRS-1^{ser307} and Akt^{ser473} in the liver. It has already been documented that there is reduction in the phosphorylation of IRS-1^{ser307} and Akt^{ser473} in the liver of either T2DM or neurodegeneration [11, 12, 75–77]. In the present study, we for the first time report that the phosphorylation of IRS-1^{ser307} and Akt^{ser473} was reduced in the cooccurring condition of T2DM and stress. Further, the combination of metformin and diazepam improved the insulin resistance in part by increasing the phosphorylation of IRS-1^{ser307} and Akt^{ser473} in the liver of the cooccurring T2DM and stress exposed animals.

Mitochondria function and integrity are impaired in both T2DM and stress and also in the cooccurring condition of T2DM and stress in brain tissues [7, 18]. Similar to earlier observations, the present study revealed that the cooccurring T2DM and stress condition cause hyperactivity of the mitochondrial SDH enzyme and loss in the mitochondrial integrity in all the brain regions [7, 18]. Further, metformin and diazepam reversed the mitochondrial SDH hyperactivity and loss in integrity in all the brain regions in the T2DM rats also exposed to repeated stress paradigm. It has been reported

that metformin restores the brain mitochondrial function in diabetic condition [78, 79]. However, this is the first report on effect of metformin in repeated stress exposed diabetic rats. In addition, metformin and diazepam combination further attenuated the mitochondrial SDH hyperactivity and loss in integrity in all the brain regions in cooccurring T2DM and stress condition. Diazepam has been shown to modulate mitochondrial activity in the brain tissues [30]. Thus, the combination therapy of metformin and diazepam may have potential mitochondrial-dependent activity in addition to glucocorticoid-mediated mechanism in this condition.

The relationship between lipid oxidative damage and mitochondrial function and integrity is well established in T2DM, stress, and their cooccurring condition [7, 21, 80]. Similar to earlier findings, the present study reveals that the extent of LPO was higher in the cooccurring condition of T2DM and stress in all the brain regions [7, 21, 80]. Metformin and diazepam mitigated the extent of LPO in all the brain regions in T2DM rats also exposed to repeated stress. It has been reported that metformin decreases diabetes-induced increase in LPO in the brain regions [81]. However, this is the first time we report the effect of metformin and diazepam on the extent of LPO in different brain regions in cooccurring T2DM and stress paradigm. The combination of metformin and diazepam attenuated the increase in the extent of LPO in all the brain regions in T2DM rats subjected to repeated CRS paradigm. Moreover, reports also suggest that there is attenuation in the antioxidant defense system in the brain tissues in T2DM, stress, and their cooccurring condition [7, 82]. In the present study, the combination of metformin and diazepam mitigated the decrease in the antioxidant enzyme activities such as SOD and CAT in all the brain regions in T2DM rats subjected to repeated stress than either monotherapy. Hence, it can be assumed that by improving the antioxidant defense system the combination of metformin and diazepam restores mitochondrial function and integrity and attenuates mitochondrial oxidative damage in all the brain regions.

In conclusion, metformin exhibited antidiabetic effect in addition to antistress and anxiolytic-like activity in the cooccurring condition of T2DM and stress. Further, metformin along with diazepam showed pronounced antidiabetic, antistress, and anxiolytic-like effects compared to metformin monotherapy in the above condition. This indicates synergistic effect of the combination. Further, the combination improved glucose tolerance, insulin sensitivity, and resistance in the above condition. The combined regimen improved the mitochondrial function, integrity, and oxidative stress in all the brain regions in the cooccurring condition of T2DM and stress. Thus, metformin in combination with diazepam may be a better therapeutic candidate in the pharmacotherapy of cooccurring condition of T2DM and stress.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgment

Debapriya Garabadu is thankful to the Council of Scientific and Industrial Research (CSIR), New Delhi, for the Senior Research Fellowship (9/13 (366)/2011-EMR-I).

References

- [1] J. E. Shaw, R. A. Sicree, and P. Z. Zimmet, "Global estimates of the prevalence of diabetes for 2010 and 2030," *Diabetes Research and Clinical Practice*, vol. 87, no. 1, pp. 4–14, 2010.
- [2] D. J. Magliano, E. L. M. Barr, P. Z. Zimmet et al., "Glucose indices, health behaviors, and incidence of diabetes in Australia: the Australian diabetes, obesity and lifestyle study," *Diabetes Care*, vol. 31, no. 2, pp. 267–272, 2008.
- [3] S. M. Southwick, M. Vythilingam, and D. S. Charney, "The psychobiology of depression and resilience to stress: implications for prevention and treatment," *Annual Review of Clinical Psychology*, vol. 1, pp. 255–291, 2005.
- [4] M. Kumari, J. Head, and M. Marmot, "Prospective study of social and other risk factors for incidence of type 2 diabetes in the Whitehall II study," *Archives of Internal Medicine*, vol. 164, no. 17, pp. 1873–1880, 2004.
- [5] A. Heraclides, T. Chandola, D. R. Witte, and E. J. Brunner, "Psychosocial stress at work doubles the risk of type 2 diabetes in middle-aged women: evidence from the Whitehall II study," *Diabetes Care*, vol. 32, no. 12, pp. 2230–2235, 2009.
- [6] M. P. Cosgrove, L. A. Sargeant, R. Caleyachetty, and S. J. Griffin, "Work-related stress and Type 2 diabetes: systematic review and meta-analysis," *Occupational Medicine*, vol. 62, no. 3, pp. 167–173, 2012.
- [7] D. Garabadu and S. Krishnamurthy, "Temporal effect of repeated stress on type-2 experimental diabetes," in *Diabetes Mellitus and Human Health Care: A Holistic Approach to Diagnosis and Treatment*, A. George, R. Augustine, and M. Sebastian, Eds., pp. 357–392, Apple Academic Press, New Jersey, NJ, USA, 2013.
- [8] M. Stumvoll, B. J. Goldstein, and T. W. van Haeften, "Type 2 diabetes: principles of pathogenesis and therapy," *The Lancet*, vol. 365, no. 9467, pp. 1333–1346, 2005.
- [9] W.-Q. Zhao and M. Townsend, "Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease," *Biochimica et Biophysica Acta—Molecular Basis of Disease*, vol. 1792, no. 5, pp. 482–496, 2009.
- [10] M. Y. Donath and S. E. Shoelson, "Type 2 diabetes as an inflammatory disease," *Nature Reviews Immunology*, vol. 11, no. 2, pp. 98–107, 2011.
- [11] G. S. Hotamisligil, R. S. Johnson, R. J. Distel, R. Ellis, V. E. Papaioannou, and B. M. Spiegelman, "Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein," *Science*, vol. 274, no. 5291, pp. 1377–1379, 1996.
- [12] J. E. Pessin and A. R. Saltiel, "Signaling pathways in insulin action: molecular targets of insulin resistance," *Journal of Clinical Investigation*, vol. 106, no. 2, pp. 165–169, 2000.
- [13] V. Aguirre, E. D. Werner, J. Giraud, Y. H. Lee, S. E. Shoelson, and M. F. White, "Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action," *Journal of Biological Chemistry*, vol. 277, no. 2, pp. 1531–1537, 2002.

- [14] S. E. Shoelson, J. Lee, and A. B. Goldfine, "Inflammation and insulin resistance," *Journal of Clinical Investigation*, vol. 116, no. 7, pp. 1793–1801, 2006.
- [15] Z. Li, K.-I. Okamoto, Y. Hayashi, and M. Sheng, "The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses," *Cell*, vol. 119, no. 6, pp. 873–887, 2004.
- [16] S. Chen, G. C. Owens, K. L. Crossin, and D. B. Edelman, "Serotonin stimulates mitochondrial transport in hippocampal neurons," *Molecular and Cellular Neuroscience*, vol. 36, no. 4, pp. 472–483, 2007.
- [17] S. Chen, G. C. Owens, and D. B. Edelman, "Dopamine inhibits mitochondrial motility in hippocampal neurons," *PLoS ONE*, vol. 3, no. 7, Article ID e2804, 2008.
- [18] S. Cardoso, M. S. Santos, A. Moreno, and P. I. Moreira, "UCP2 and ANT differently modulate proton-leak in brain mitochondria of long-term hyperglycemic and recurrent hypoglycemic rats," *Journal of Bioenergetics and Biomembranes*, vol. 45, no. 4, pp. 397–407, 2013.
- [19] T. V. Fiorentino, A. Priolella, P. Zuo, and F. Folli, "Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases," *Current Pharmaceutical Design*, vol. 19, no. 32, pp. 5695–5703, 2013.
- [20] V. V. Davydov and I. V. Volkova, "Effect of stress on the content of free radical oxidation products in subcellular brain fractions in rats of pubertal age," *Ukrain'skyi Biokhimichnyi Zhurnal*, vol. 81, no. 2, pp. 102–106, 2009.
- [21] K. A. Rasbach and R. G. Schnellmann, "Signaling of mitochondrial biogenesis following oxidant injury," *Journal of Biological Chemistry*, vol. 282, no. 4, pp. 2355–2362, 2007.
- [22] M. O. Goodarzi and M. Bryer-Ash, "Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents," *Diabetes, Obesity and Metabolism*, vol. 7, no. 6, pp. 654–665, 2005.
- [23] D. M. Nathan, J. B. Buse, M. B. Davidson et al., "Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American diabetes association and the European association for the study of diabetes," *Diabetologia*, vol. 52, no. 1, pp. 17–30, 2009.
- [24] M. Foretz, S. Hébrard, J. Leclerc et al., "Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state," *Journal of Clinical Investigation*, vol. 120, no. 7, pp. 2355–2369, 2010.
- [25] M.-Y. El-Mir, V. Nogueira, E. Fontaine, N. Avéret, M. Rigoulet, and X. Leverve, "Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I," *Journal of Biological Chemistry*, vol. 275, no. 1, pp. 223–228, 2000.
- [26] B. Guigas, D. Daille, C. Chauvin et al., "Metformin inhibits mitochondrial permeability transition and cell death: a pharmacological in vitro study," *Biochemical Journal*, vol. 382, no. 3, pp. 877–884, 2004.
- [27] S. Okada, K. Ichiki, S. Tanokuchi, K. Ishii, H. Hamada, and Z. Ota, "Effect of an anxiolytic on lipid profile in non-insulin dependent diabetes mellitus," *Journal of International Medical Research*, vol. 22, no. 6, pp. 338–342, 1994.
- [28] S. Okada, K. Ichiki, S. Tanokuchi, K. Ishii, H. Hamada, and Z. Ota, "How blood pressure in patients with non-insulin-dependent diabetes mellitus is influenced by stress," *Journal of International Medical Research*, vol. 23, no. 5, pp. 377–380, 1995.
- [29] F. A. A. Al-Ahmed, E. S. M. El-Denshary, M. Zaki, H. A. El-Sawaf, and A. R. Abu-Jayyab, "Interaction between diazepam and oral antidiabetic agents on serum glucose, insulin and chromium levels in rats," *Bioscience Reports*, vol. 9, no. 3, pp. 347–350, 1989.
- [30] A. Sarnowska, M. Beresewicz, B. Zabłocka, and K. Domańska-Janik, "Diazepam neuroprotection in excitotoxic and oxidative stress involves a mitochondrial mechanism additional to the GABAAR and hypothermic effects," *Neurochemistry International*, vol. 55, no. 1–3, pp. 164–173, 2009.
- [31] B. Chelli, A. Lena, R. Vanacore et al., "Peripheral benzodiazepine receptor ligands: mitochondrial transmembrane potential depolarization and apoptosis induction in rat C6 glioma cells," *Biochemical Pharmacology*, vol. 68, no. 1, pp. 125–134, 2004.
- [32] L. Marselli, L. Trincavelli, C. Santangelo et al., "The role of peripheral benzodiazepine receptors on the function and survival of isolated human pancreatic islets," *European Journal of Endocrinology*, vol. 151, no. 2, pp. 207–214, 2004.
- [33] P. Masiello, C. Broca, R. Gross et al., "Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide," *Diabetes*, vol. 47, no. 2, pp. 224–229, 1998.
- [34] R. M. Sullivan and H. Szechtman, "Asymmetrical influence of mesocortical dopamine depletion on stress ulcer development and subcortical dopamine systems in rats: implications for psychopathology," *Neuroscience*, vol. 65, no. 3, pp. 757–766, 1995.
- [35] R. Yanardag, O. Ozsoy-Sacan, S. Bolkent, H. Orak, and O. Karabulut-Bulan, "Protective effects of metformin treatment on the liver injury of streptozotocin-diabetic rats," *Human and Experimental Toxicology*, vol. 24, no. 3, pp. 129–135, 2005.
- [36] D. Beattie, "Effect of drugs on rats exposed to cold-restraint stress," *Journal of Pharmacy and Pharmacology*, vol. 29, no. 12, pp. 748–751, 1977.
- [37] D. Kumar, Z. A. Bhat, V. Kumar, W. Y. Raja, and M. Y. Shah, "Anti-anxiety activity of *Stachys tibetica* Vatke," *Chinese Journal of Natural Medicines*, vol. 11, no. 3, pp. 240–244, 2013.
- [38] M. Palkovits and M. J. Brownstein, *Maps and Guide to Microdissection of the Rat Brain*, Elsevier, New York, NY, USA, 1988.
- [39] J. M. Rijkkelijkhuizen, T. Doesburg, C. J. Girman et al., "Hepatic fat is not associated with β -cell function or postprandial free fatty acid response," *Metabolism: Clinical and Experimental*, vol. 58, no. 2, pp. 196–203, 2009.
- [40] Q. Wang, C. Jiang, S. Fang et al., "Antihyperglycemic, antihyperlipidemic and antioxidant effects of ethanol and aqueous extracts of *Cyclocarya paliurus* leaves in type 2 diabetic rats," *Journal of Ethnopharmacology*, vol. 150, no. 3, pp. 1119–1127, 2013.
- [41] A. Duseja, K. K. Thumburu, A. Das et al., "Insulin tolerance test is comparable to homeostasis model assessment for insulin resistance in patients with nonalcoholic fatty liver disease," *Indian Journal of Gastroenterology*, vol. 26, no. 4, pp. 170–173, 2007.
- [42] R. Muniyappa, S. Lee, H. Chen, and M. J. Quon, "Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage," *The American Journal of Physiology—Endocrinology and Metabolism*, vol. 294, no. 1, pp. E15–E26, 2008.
- [43] P. M. Toleikis and D. V. Godin, "Alteration of antioxidant status in diabetic rats by chronic exposure to psychological stressors," *Pharmacology Biochemistry and Behavior*, vol. 52, no. 2, pp. 355–366, 1995.

- [44] C. J. H. Woodward and P. W. Emery, "Determination of plasma corticosterone using high-performance liquid chromatography," *Journal of Chromatography*, vol. 419, pp. 280–284, 1987.
- [45] D. Garabadu, A. Shah, A. Ahmad et al., "Eugenol as an anti-stress agent: modulation of hypothalamic-pituitary- adrenal axis and brain monoaminergic systems in a rat model of stress," *Stress*, vol. 14, no. 2, pp. 145–155, 2011.
- [46] K. Sairam, C. V. Rao, M. D. Babu, K. V. Kumar, V. K. Agrawal, and R. K. Goel, "Antilcerogenic effect of methanolic extract of *Embllica officinalis*: an experimental study," *Journal of Ethnopharmacology*, vol. 82, no. 1, pp. 1–9, 2002.
- [47] S. Pellow, P. Chopin, S. E. File, and M. Briley, "Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat," *Journal of Neuroscience Methods*, vol. 14, no. 3, pp. 149–167, 1985.
- [48] M. M. Bradford, "A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding," *Analytical Biochemistry*, vol. 72, no. 1-2, pp. 248–254, 1976.
- [49] P. L. Pedersen, J. W. Greenawalt, B. Reynafarje et al., "Preparation and characterization of mitochondria and submitochondrial particles of rat liver and liver-derived tissues," *Methods in Cell Biology*, vol. 20, pp. 411–481, 1978.
- [50] O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall, "Protein measurement with the Folin phenol reagent," *The Journal of Biological Chemistry*, vol. 193, no. 1, pp. 265–275, 1951.
- [51] S. L. Old and M. A. Johnson, "Methods of microphotometric assay of succinate dehydrogenase and cytochrome C oxidase activities for use on human skeletal muscle," *Histochemical Journal*, vol. 21, no. 9-10, pp. 545–555, 1989.
- [52] S.-G. Huang, "Development of a high throughput screening assay for mitochondrial membrane potential in living cells," *Journal of Biomolecular Screening*, vol. 7, no. 4, pp. 383–389, 2002.
- [53] M. Uchiyama and M. Mihara, "Determination of malonaldehyde precursor in tissues by thiobarbituric acid test," *Analytical Biochemistry*, vol. 86, no. 1, pp. 271–278, 1978.
- [54] F. W. Sunderman Jr., A. Marzouk, S. M. Hopfer, O. Zaharia, and M. C. Reid, "Increased lipid peroxidation in tissues of nickel chloride-treated rats," *Annals of Clinical and Laboratory Science*, vol. 15, no. 3, pp. 229–236, 1985.
- [55] P. Kakkar, B. Das, and P. N. Viswanathan, "A modified spectrophotometric assay of superoxide dismutase," *Indian Journal of Biochemistry and Biophysics*, vol. 21, no. 2, pp. 130–132, 1984.
- [56] R. F. Beers Jr. and I. W. Sizer, "A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase," *The Journal of Biological Chemistry*, vol. 195, no. 1, pp. 133–140, 1952.
- [57] T. A. Buchanan, A. H. Xiang, R. K. Peters et al., "Preservation of pancreatic β -cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women," *Diabetes*, vol. 51, no. 9, pp. 2796–2803, 2002.
- [58] L. H. Gao, Q. Liu, S. N. Liu et al., "A refined-JinQi-JiangTang tablet ameliorates prediabetes by reducing insulin resistance and improving beta cell function in mice," *Journal of Ethnopharmacology*, vol. 151, no. 1, pp. 675–685, 2014.
- [59] K. Okada, T. Hirano, J. Ran, and M. Adachi, "Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats," *Hypertension Research*, vol. 27, no. 4, pp. 293–299, 2004.
- [60] E. P. Davila, H. Florez, M. J. Trepka et al., "Long work hours is associated with suboptimal glycemic control among US workers with diabetes," *The American Journal of Industrial Medicine*, vol. 54, no. 5, pp. 375–383, 2011.
- [61] M. Faulenbach, H. Uthoff, K. Schwegler, G. A. Spinaz, C. Schmid, and P. Wiesli, "Effect of psychological stress on glucose control in patients with type 2 diabetes," *Diabetic Medicine*, vol. 29, no. 1, pp. 128–131, 2012.
- [62] B. Karamanos, A. Thanopoulou, V. Drossinos, E. Charalampidou, S. Sourmeli, and A. Archimandritis, "Study comparing the effect of pioglitazone in combination with either metformin or sulphonylureas on lipid profile and glycaemic control in patients with type 2 diabetes (ECLA)," *Current Medical Research and Opinion*, vol. 27, no. 2, pp. 303–313, 2011.
- [63] F. Chen, H. Xiong, J. Wang, X. Ding, G. Shu, and Z. Mei, "Antidiabetic effect of total flavonoids from *Sanguis draxonis* in type 2 diabetic rats," *Journal of Ethnopharmacology*, vol. 149, no. 3, pp. 729–736, 2013.
- [64] T.-Y. Wang, X.-Q. Chen, J.-Z. Du, N.-Y. Xu, C.-B. Wei, and W. W. Vale, "Corticotropin-releasing factor receptor type 1 and 2 mRNA expression in the rat anterior pituitary is modulated by intermittent hypoxia, cold and restraint," *Neuroscience*, vol. 128, no. 1, pp. 111–119, 2004.
- [65] A. Kumar, S. Aravamudhan, M. Gordic, S. Bhansali, and S. S. Mohapatra, "Ultrasensitive detection of cortisol with enzyme fragment complementation technology using functionalized nanowire," *Biosensors and Bioelectronics*, vol. 22, no. 9-10, pp. 2138–2144, 2007.
- [66] C. de Oliveira, A. B. de Mattos, C. Biz, L. M. Oyama, E. B. Ribeiro, and C. M. O. Do Nascimento, "High-fat diet and glucocorticoid treatment cause hyperglycemia associated with adiponectin receptor alterations," *Lipids in Health and Disease*, vol. 10, article 11, 2011.
- [67] S. Krishnamurthy, D. Garabadu, and N. R. Reddy, "Asparagus racemosus modulates the hypothalamic-pituitary-adrenal axis and brain monoaminergic systems in rats," *Nutritional Neuroscience*, vol. 16, no. 6, pp. 255–261, 2013.
- [68] M. E. Cleasby, D. E. W. Livingstone, M. J. Nyirenda, J. R. Seckl, and B. R. Walker, "Is programming of glucocorticoid receptor expression by prenatal dexamethasone in the rat secondary to metabolic derangement in adulthood?" *European Journal of Endocrinology*, vol. 148, no. 1, pp. 129–138, 2003.
- [69] E. Carrizo, V. Fernández, I. Sandia et al., "Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study," *Schizophrenia Research*, vol. 113, no. 1, pp. 19–26, 2009.
- [70] C. López-Rubalcava, N. Paez-Martinez, and J. Oikawa, "Blockade of corticosteroid receptors induces anxiolytic-like effects in streptozotocin-induced diabetic mice, and synergizes with diazepam," *Behavioural Pharmacology*, vol. 24, no. 4, pp. 320–327, 2013.
- [71] C. Lloyd, J. Smith, and K. Weinger, "Stress and diabetes: a review of the links," *Diabetes Spectrum*, vol. 18, no. 2, pp. 121–127, 2005.
- [72] L. Fisher, J. T. Mullan, M. M. Skaff, R. E. Glasgow, P. Arean, and D. Hessler, "Predicting diabetes distress in patients with Type 2 diabetes: a longitudinal study," *Diabetic Medicine*, vol. 26, no. 6, pp. 622–627, 2009.
- [73] R. J. Anderson, M. de Groot, A. B. Grigsby et al., "Anxiety and poor glycemic control: a meta-analytic review of the literature," *International Journal of Psychiatry in Medicine*, vol. 32, no. 3, pp. 235–247, 2002.

- [74] L. A. Hilakivi-Clarke, K. M. Wozniak, M. J. Durcan, and M. Linnoila, "Behavior of streptozotocin-diabetic mice in tests of exploration, locomotion, anxiety, depression and aggression," *Physiology and Behavior*, vol. 48, no. 3, pp. 429–433, 1990.
- [75] A. R. Saltiel and C. R. Kahn, "Insulin signalling and the regulation of glucose and lipid metabolism," *Nature*, vol. 414, no. 6865, pp. 799–806, 2001.
- [76] A. R. Saltiel and J. E. Pessin, "Insulin signaling pathways in time and space," *Trends in Cell Biology*, vol. 12, no. 2, pp. 65–71, 2002.
- [77] J. F. Vecina, A. G. Oliveira, T. G. Araujo et al., "Chlorella modulates insulin signaling pathway and prevents high-fat diet-induced insulin resistance in mice," *Life Sciences*, vol. 95, no. 1, pp. 45–52, 2014.
- [78] M.-Y. El-Mir, D. Daille, G. R-Villanueva et al., "Neuroprotective role of antidiabetic drug metformin against apoptotic cell death in primary cortical neurons," *Journal of Molecular Neuroscience*, vol. 34, no. 1, pp. 77–87, 2008.
- [79] H. Pintana, N. Apaijai, W. Pratchayasakul, N. Chattipakorn, and S. C. Chattipakorn, "Effects of metformin on learning and memory behaviors and brain mitochondrial functions in high fat diet induced insulin resistant rats," *Life Sciences*, vol. 91, no. 11-12, pp. 409–414, 2012.
- [80] K. Fukui, K. Onodera, T. Shinkai, S. Suzuki, and S. Urano, "Impairment of learning and memory in rats caused by oxidative stress and aging, and changes in antioxidative defense systems," *Annals of the New York Academy of Sciences*, vol. 928, pp. 168–175, 2001.
- [81] P. Bhutada, Y. Mundhada, K. Bansod et al., "Protection of cholinergic and antioxidant system contributes to the effect of berberine ameliorating memory dysfunction in rat model of streptozotocin-induced diabetes," *Behavioural Brain Research*, vol. 220, no. 1, pp. 30–41, 2011.
- [82] K. O. Menabde, G. M. Burdzhnandze, M. V. Chachua, Z. T. Kuchukashvily, and N. I. Koshorydze, "Tissue specificity of lipid peroxidation under emotional stress in rats," *Ukrainskii Biokhimicheskii Zhurnal*, vol. 83, no. 3, pp. 85–90, 2011.



Hindawi

Submit your manuscripts at
<http://www.hindawi.com>

